Insider Selling: Loxo Oncology, Inc. (LOXO) Major Shareholder Sells $37,500,000.00 in Stock
Loxo Oncology, Inc. (NASDAQ:LOXO) major shareholder Aisling Capital Iii Lp sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total transaction of $37,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Loxo Oncology, Inc. (NASDAQ:LOXO) opened at $73.62 on Thursday. Loxo Oncology, Inc. has a 12-month low of $25.25 and a 12-month high of $95.92.
Several research analysts recently commented on the stock. BidaskClub raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price target on the stock in a research note on Wednesday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $94.00 price target (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. Citigroup reduced their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, November 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $75.00 price target on shares of Loxo Oncology in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $90.57.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Stock Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related stocks with our FREE daily email newsletter.